Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Gastric Cancer
and you are
between 20 and 80
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.

Provided treatments

  • Drug: Nivolumab
  • Drug: Tegafur-gimeracil-oteracil potassium
  • Drug: Oxaliplatin
  • Drug: Capecitabine
  • Drug: Placebo
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03006705. The sponsor of the trial is Ono Pharmaceutical Co. Ltd and it is looking for 700 volunteers for the current phase.
Official trial title:
A Multicenter, Double-blind, Randomized Study in Patients With Gastric Cancer Undergoing Postoperative Adjuvant Chemotherapy